Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 is an investor presentation that Annexon, Inc. (the "Company") plans to present during the 41st Annual J.P. Morgan Healthcare Conference commencing on January 9, 2023.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.




Item 8.01 Other Events.

On January 8, 2023, the Company provided a corporate update. A copy of the press release, titled "Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises," is filed as Exhibit 99.2 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit No.      Description

99.1               Company Presentation, dated January 2023.

99.2               Press Release, dated January 8, 2023, titled "Annexon Highlights
                 Strategic Focus to Advance Four Flagship Complement Programs
                 through Late-Stage Development and Progress Across Three
                 Therapeutic Franchises."

104.1            Cover Page Interactive Data File, formatted in inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses